For instance, poly (ADP-ribose) polymerase (PARP) inhibiting drugs, is used in managing patients with ovarian cancer [23] and breast cancer [24] in cases of pathogenic BRCA-1/2 -gene mutations. This evidence concerns the gene BRCA1 and ovarian carcinoma.